Fig. 3
From: Efficacy of galcanezumab in migraine central sensitization
Overall CSI score changes. The mean CSI score at baseline was 36.0 and showed a significant decrease to 29.7 at 3 months (p < 0.001 [7e−8] vs. baseline) and to 29.3 at 6 months (p < 0.001 [1e−8] vs. baseline). CSI: Central Sensitization Inventory; SD: standard deviation.
